logo dha

DHA

10/03/2025
08:00
Horário oficial: Brasília

10/03/2025
Cardiologia
Português
logo dha

Seguindo

Sobre este conteúdo

Mini Review
Special issue: Renal denervation: Evidence and challenges in clinical practice.
Published: 11 April 2024
Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?)

Keisuke Okamura,
Hideaki Shimada,
Keisuke Imazato,
Hideto Sako,
Akihiro Udo,
Kenichiro Taniguchi,
Shogo Morisaki,
Ichiro Imamura,
Hidenori Urata,
Hisatomi Arima &
Shin-ichiro Miura
Hypertension Research volume 47, pages2652–2658 (2024)Cite this article

 

 

Abstract

The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.

 

Mini Review
Special issue: Renal denervation: Evidence and challenges in clinical practice.
Published: 11 April 2024
Impact of renal denervation on quality of life (How does renal denervation contribute to improving hypertension treatment affected by poor medication adherence?)

Keisuke Okamura,
Hideaki Shimada,
Keisuke Imazato,
Hideto Sako,
Akihiro Udo,
Kenichiro Taniguchi,
Shogo Morisaki,
Ichiro Imamura,
Hidenori Urata,
Hisatomi Arima &
Shin-ichiro Miura
Hypertension Research volume 47, pages2652–2658 (2024)Cite this article

 

 

Abstract

The US Food and Drug Administration has approved renal denervation (RDN) as a new treatment option for hypertension (HT) because it not only has antihypertensive effects but also improves the quality of blood pressure (BP) reduction. RDN is expected to be increasingly used in clinical practice in the future. This review summarizes the impact of RDN on quality of life (QOL). Although the treatment of HT aims to improve life prognosis, the use of antihypertensive agents can impair QOL because of adverse effects and lifestyle changes associated with long-term medication use. Consequently, poor adherence to antihypertensive agents is a common problem and may be the most important issue affecting patient QOL. In RDN trials in patients taking antihypertensive agents, approximately 40% of patients had poor adherence to the drugs. Poor adherence is often the cause of resistant hypertension. Therefore, RDN should be well suited to treating HT and improving QOL. Studies have shown that approximately 30% of HT patients prefer RDN to drug treatment. Patients who prefer RDN are typically male and younger and have high BP, poor adherence, and a history of adverse effects of antihypertensive agents. We hope that RDN will improve not only life prognosis but also QOL in HT patients because of its benefits for adherence. Furthermore, we expect that in the future, RDN will be used in other sympathetic nervous system-related diseases, such as heart failure, atrial fibrillation, and sleep apnea syndrome.

 

Comentários

Deixe um comentário

26 Aulas
60 Horas
19 Aulas
30 Horas

Comentários

Deixe um comentário

Cardiologia Preventiva: Estratégias Para Reduzir O Impacto Da Morbimortalidade Cardiovascular
Íntegra
29/09/2020
Thumb Live Sbc Pr 12/04
01:26:26
Íntegra
12/04/2022
Captura De Tela 2023-10-18 092555
00:52:25
Íntegra
17/10/2023
Thumb (66)
01:08:37
Íntegra
17/02/2025
Thumb (8)
01:31:28
Íntegra
29/07/2024
Screenshot_3
12:38

DIC

Corte
04/12/2023
Screenshot_7
13:43
Corte
26/04/2021
Imagem_2023-08-30_154721783
01:35:38
Íntegra
29/08/2023
Slide - 10º Palestra

DHA

Íntegra
24/04/2021
Screenshot_1
35:55

DIC

Corte
26/09/2022
Screenshot_1
Íntegra
27/09/2021
[Sbc Pr] Simpósio Dac: Atualidades Em Síndrome Coronária Aguda
Íntegra
01/12/2020
Kit-Mkt-Socerj-Thumb-Podcast
14:27
Podcast
02/04/2025
Encontro De Ecocardiografia Do Departamento De Ecocardiografia Da Socergs
Íntegra
07/08/2021
Thumb
44:49
Vídeo
18/09/2024
Carrinho de compras